NF-κB Inhibitor Compounds for Selective Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Inappropriate or excessive activation of the NF-κB regulatory pathway leads to excessive inflammation, which can cause various disease states, including autoimmune conditions and chronic inflammation, for which there is a need for effective inhibitors to manage NF-κB activity.
Innovation Solution
Development of organic compounds and formulations to inhibit NF-κB activity within cells, administered to mammals to treat conditions such as Crohn's disease, ulcerative colitis, psoriatic arthritis, systemic lupus, and psoriasis, by targeting specific structural components of the compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NF-κB pathway is activated to respond to pathogens, then immune response is enhanced, but excessive inflammation occurs leading to harmful effects
Solution Approach 1:
The patent employs small molecule compounds that bind to and modulate NF-κB pathway components, changing the activation parameters of the pathway to prevent excessive inflammation while maintaining necessary immune responses. The compounds alter the threshold and duration of NF-κB activation to achieve therapeutic effect.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that mediate between pathogen detection and NF-κB activation. These compounds selectively interfere with specific interactions in the NF-κB pathway, acting as molecular mediators that fine-tune the immune response and prevent harmful inflammation.
2Object-affected harmful factors
If NF-κB activity is inhibited to reduce inflammation, then harmful inflammatory effects are reduced, but immune response to pathogens may be compromised
Solution Approach 1:
The patent achieves local quality control by targeting specific components or interaction points within the NF-κB pathway using small molecule compounds. This localized intervention allows selective modulation of inflammatory responses while preserving other essential immune functions that do not depend on the targeted pathway elements.
Solution Approach 2:
The patent applies partial inhibition of NF-κB activity rather than complete blockade. The small molecule compounds provide dose-dependent or graded inhibition, allowing sufficient NF-κB activity for pathogen response while preventing excessive activation that leads to harmful inflammation. This partial action strategy balances immune protection with inflammation control.
Data Source
AI summary
This document provides compounds that are inhibitors of NF-κB activity, as well as the methods of using such compounds for treating diseases and conditions such as cancer, inflammatory conditions, or autoimmune diseases.